Is Amgen's Cholesterol Drug Repatha Worth Its Hefty Price Tag?
Repatha costs $14,000 per year before discounts.
In a 27,000-patient clinical trial, Amgen's (AMGN) - Get Report Repatha reduced the risk of heart attacks, strokes and other heart-related health problems by 15% compared to a placebo. But the results may not be enough for investors who expected Repatha to show a cardiovascular risk reduction of 20-22%. Compounding the issue, 75% of prescriptions written for Repatha are rejected by insurance companies. The rejections may have to do with the fact that Repatha costs $14,000 per year before discounts.
READ THE FULL STORY HERE: Amgen Cholesterol Drug Cuts Risk of Heart Attack, Stroke but Not Enough to Quell Value Debate
This article was written by a staff member of TheStreet.
